Live-attenuated SIV strains provide an important model to study cellular and viral determinants that contribute to disease development and they also provide a unique tool to study mechanisms leading to protective immunity. We study the regulated expression of HIV which is mediated via the viral Rev protein with the goal to evaluate the role of Rev in pathogenesis. Our discovery of other RNA export mechanisms (mediate via cellular RNA export factors and retroviral RNA export elements CTE, RTE) provided the key tools to generate HIV and SIV variants that have the Rev/RRE regulatory system replaced. CTE or RTE provide us also with useful tools to achieve efficient expression of HIV and SIV structural protein in simple DNA vectors used as vaccine approaches against AIDS. Importantly, we found that our Rev-independent SIV strains are not pathogenic in rhesus macaques, which demonstrates that the Rev regulation plays an important role in pathogenicity of SIV. Replacement of the natural regulatory controls of Rev-RRE by the CTE provides a novel approach to lower the virulence of a pathogenic lentivirus. These studies provide critical information about the establishment and maintenance of host immune responses during chronic retroviral infections with distinct pathogenic outcomes. Macaques immunized with attenuated viruses develop persistent humoral and cellular immune responses, able to protect the animals from highly pathogenic SIV challenge. Therefore, these live-attenuated SIV strains provide us not only with a unique tool to dissect cellular and viral determinants that contribute to AIDS development, but are also useful for studying correlates of protective immunity. These studies will provide critical information about the establishment and maintenance of host immune responses during chronic retroviral infections with distinct pathogenic outcomes.To study prevention of AIDS, we have a long-standing collaboration with George Pavlakis (Human Retrovirus Section, Vaccine Branch), and we have generated efficient DNA expression vectors, which are currently evaluated as vaccines against SIV and HIV. This work is based on the previous recognition that RNA elements (called INS) present within the gag/pol and env coding regions of HIV are responsible for nuclear retention and instability of the transcripts in the absence of Rev, and that these elements can be eliminated by changing the RNA composition without affecting the amino acid sequence. These RNA optimized gag and env expression vectors mediate the development of protective immune responses in vaccinated macaques when used as DNA only as well as DNA prime vaccine modality. We also found that a combination of DNA vaccine vectors producing native and modified antigens are able to induce immune responses able to protect from high viremia in the rhesus macaque/SIVmac251 model. On-going studies focus on evaluating the efficacy of these further optimized DNA based vaccine vectors both as preventive and therapeutic vaccine modalities.

Agency
National Institute of Health (NIH)
Institute
Division of Basic Sciences - NCI (NCI)
Type
Intramural Research (Z01)
Project #
1Z01BC010350-05
Application #
7052679
Study Section
Vector Biology Study Section (VB)
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
2004
Total Cost
Indirect Cost
Name
Basic Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Bergamaschi, Cristina; Jalah, Rashmi; Kulkarni, Viraj et al. (2009) Secretion and biological activity of short signal peptide IL-15 is chaperoned by IL-15 receptor alpha in vivo. J Immunol 183:3064-72
von Gegerfelt, Agneta S; Rosati, Margherita; Alicea, Candido et al. (2007) Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunization. J Virol 81:1972-9
Robinson, T M; Sidhu, M K; Pavlakis, G N et al. (2007) Macaques co-immunized with SIVgag/pol-HIVenv and IL-12 plasmid have increased cellular responses. J Med Primatol 36:276-84
Egan, Michael A; Megati, Shakuntala; Roopchand, Vidia et al. (2006) Rational design of a plasmid DNA vaccine capable of eliciting cell-mediated immune responses to multiple HIV antigens in mice. Vaccine 24:4510-23
Hel, Zdenek; Tsai, Wen-Po; Tryniszewska, Elzbieta et al. (2006) Improved vaccine protection from simian AIDS by the addition of nonstructural simian immunodeficiency virus genes. J Immunol 176:85-96
Schadeck, Eva B; Sidhu, Maninder; Egan, Michael A et al. (2006) A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques. Vaccine 24:4677-87
Kumar, Sanjeev; Yan, Jian; Muthumani, Karuppiah et al. (2006) Immunogenicity testing of a novel engineered HIV-1 envelope gp140 DNA vaccine construct. DNA Cell Biol 25:383-92
von Gegerfelt, Agneta S; Alicea, Candido; Valentin, Antonio et al. (2006) Long lasting control and lack of pathogenicity of the attenuated Rev-independent SIV in rhesus macaques. AIDS Res Hum Retroviruses 22:516-28
Kutzler, Michele A; Robinson, Tara M; Chattergoon, Michael A et al. (2005) Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J Immunol 175:112-23
Rosati, Margherita; von Gegerfelt, Agneta; Roth, Patricia et al. (2005) DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge. J Virol 79:8480-92

Showing the most recent 10 out of 12 publications